CA29842P1053

Eupraxia Pharmaceuticals Appoints Dr. Jeymi Tambiah as Chief Medical Officer

May 01, 2026 17:05 ET  | Source: Eupraxia Pharmaceuticals Inc. VANCOUVER, British Columbia, May 01, 2026 (GLOBE NEWSWIRE) -- Eupraxia…

3 hours ago

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

March 12, 2026 21:03 ET  | Source: Eupraxia Pharmaceuticals Inc. VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia…

2 months ago

Eupraxia Pharmaceuticals Announces Closing of US$63.2 Million Public Offering Including Full Exercise of Underwriter Option

February 20, 2026 15:10 ET  | Source: Eupraxia Pharmaceuticals Inc. VICTORIA, British Columbia, Feb. 20, 2026 (GLOBE NEWSWIRE) -- Eupraxia…

2 months ago

Eupraxia Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update

Announced first patient dosed in the Phase 2b placebo-controlled portion of the EP-104GI RESOLVE trial with topline data expected in…

9 months ago